Orexigen Therapeutics, Inc. is a La Jolla, California-based biopharmaceutical company incorporated in 2002 that focuses on the treatment of obesity. The company’s primary product is Contrave®, an FDA-approved weight management medication launched in 2014 that is also marketed as Mysimba™ in Europe and other international markets. Orexigen operates through a network of distribution partners in 24 countries and employs approximately 111 people. The company is publicly traded on the NASDAQ under the ticker symbol OREX.
